The Canadian Cancer Clinical Trials Network (3CTN) is pleased to announce the next impACCT Virtual Rounds Spring Session.
When: Tuesday, May 16, 2023 12:00 pm -1:00 pm EDT
Trial #1: (UoA) ACIT001 / EXC002
A phase 1b/2 multi-center, de-centralized, dose selection study of autologous CD19-directed chimeric antigen receptor (CAR) T-cells in patients with relapsed/refractory aggressive lymphoma or acute lymphoblastic leukemia (ALL)
Speaker: Dr. Michael Chu, Assistant Professor, Department of Oncology, University of Alberta; Clinician Scientist at the Cross Cancer Institute
Trial #2: (OHRI) CLIC-01
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Speaker: Dr. Kevin Hay, Assistant Professor, Vancouver General Hospital, Clinician Scientist at the Terry Fox Laboratory and Leukemia/Bone Marrow Transplant Program of BC in Vancouver
Tags:
Posted on: